CHE compared with HALO: revenue, margins and what each company keeps, and the suppliers and customers both name

CHEChemed Corp

Mkt capRevenueRevenue

HALOHalozyme Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

CHEChemed Corp

HALOHalozyme Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

CHE2 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±7.2%▲+4.77%×0.67

Q2 FY26—▲+4.20%—

HALO1 of 4 reports

1 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±6.0%▲+20.24%×3.37

= impliedCHE realized, solidHALO realized, hatchedOne scale, both sides: full bar = 21%× = |realized| ÷ impliedSource: market data

CHEChemed Corp

534.36▼−1.40%· post 534.73

Mkt cap$7.0BRevenue$691MQ3 FY26Revenue$2.5BFY25

HALOHalozyme Therapeutics, Inc.

130.89▼−0.22%· post 130.16

ClosedOct 30 '26

Mkt cap$14.9BRevenue$481MQ2 FY26Revenue$1.4BFY25

Compare

ClosedOct 30 '26

CHEChemed Corp

HALOHalozyme Therapeutics, Inc.

534.36▼−1.40%post 534.73

Price

130.89▼−0.22%post 130.16

$7.0B

Mkt cap

$14.9B

Q3 FY26$691M

Revenue

$481MQ2 FY26

FY25$2.5B

Revenue

$1.4BFY25

CHE534.36▼−1.40%vsHALO130.89▼−0.22%ClosedOct 30 '26